Literature DB >> 4020623

A nonlinear physiologic pharmacokinetic model: I. Steady-state.

J G Wagner, G J Szpunar, J J Ferry.   

Abstract

The two-compartment model of Rowland et al., (2) has been extended by replacing first order elimination with Michaelis-Menten elimination kinetics. All of the equations for steady-state concentrations and clearances for zero order (constant rate) input orally (into compartment #2) and intravenously (into compartment #1) are derived and reported. The steady-state concentration in compartment #1, following intravenous administration, is shown to be a nonlinear function of maximal velocity of metabolism, Vm, the Michaelis constant, Km, and liver blood flow, Q; and, following oral administration is dependent only upon Vm and Km and is independent of Q. However, oral bioavailability is a function of Vm, Km, and Q. The model allows physiologic pharmacokinetic interpretation of both linear and nonlinear data; and, together with simple modification of the model, can explain much observed pharmacokinetic data to date particularly for first-pass drugs. Future articles in the series will be concerned with single doses, evaluation of literature data in terms of the model, application of the theory in toxicology and in clinical pharmacokinetics and therapeutics.

Mesh:

Substances:

Year:  1985        PMID: 4020623     DOI: 10.1007/bf01073657

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  39 in total

1.  Statistical estimations in enzyme kinetics.

Authors:  G N WILKINSON
Journal:  Biochem J       Date:  1961-08       Impact factor: 3.857

2.  Current models of hepatic elimination.

Authors:  L Bass
Journal:  Gastroenterology       Date:  1979-06       Impact factor: 22.682

3.  Clearance and biologic half-life as indices of intrinsic hepatic metabolism.

Authors:  D Perrier; M Gibaldi
Journal:  J Pharmacol Exp Ther       Date:  1974-10       Impact factor: 4.030

4.  Models of hepatic drug clearance: discrimination between the 'well stirred' and 'parallel-tube' models.

Authors:  A B Ahmad; P N Bennett; M Rowland
Journal:  J Pharm Pharmacol       Date:  1983-04       Impact factor: 3.765

5.  Predictability of verapamil steady-state plasma levels from single-dose data explained.

Authors:  J G Wagner
Journal:  Clin Pharmacol Ther       Date:  1984-07       Impact factor: 6.875

6.  A theoretical examination of the effects of gut wall metabolism, hepatic elimination, and enterohepatic recycling on estimates of bioavailability and of hepatic blood flow.

Authors:  K S Pang; J R Gillette
Journal:  J Pharmacokinet Biopharm       Date:  1978-10

7.  Flow dependence of first-order uptake of substances by heterogeneous perfused organs.

Authors:  L Bass
Journal:  J Theor Biol       Date:  1980-09-21       Impact factor: 2.691

8.  A method of determining intrinsic hepatic clearance from the first-pass effect.

Authors:  L Bass; K Winkler
Journal:  Clin Exp Pharmacol Physiol       Date:  1980 May-Jun       Impact factor: 2.557

9.  Hepatic elimination of femoxetine in pig during intravenous infusion.

Authors:  S Keiding; H Mengel; J Lund
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1983-03

10.  Verapamil kinetics in normal subjects and patients with coronary artery spasm.

Authors:  S B Freedman; D R Richmond; J J Ashley; D T Kelly
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

View more
  4 in total

Review 1.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 2.  Identifiability and indistinguishability of nonlinear pharmacokinetic models.

Authors:  K R Godfrey; M J Chapman; S Vajda
Journal:  J Pharmacokinet Biopharm       Date:  1994-06

3.  Effect of protein binding on steady-state equations.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1985-10

4.  Accumulation kinetics of propranolol in the rat: comparison of Michaelis-Menten-mediated clearance and clearance changes consistent with the "altered enzyme hypothesis".

Authors:  C Weber; K Stoeckel; D Lalka
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.